Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Infect Dis. 2008 Dec 15;47(12):1587-92. doi: 10.1086/593310.

New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis.

Author information

  • 1Center for Biologics Evaluation and Research, US Food and Drug Administration, Rockville, Maryland 20852, USA. konstantin.chumakov@fda.hhs.gov

Abstract

Twenty years of global polio eradication efforts may soon eliminate the transmission of wild-type poliovirus. However, new information that has been learned about poliovirus, as well as the political realities of a modern world, demand that universal immunity against poliomyelitis be maintained, even after wild-type poliovirus is eradicated. Although 2 excellent vaccines have proven to be highly effective in the past, neither the live-attenuated vaccine nor the currently used inactivated vaccine are optimal for use in the posteradication era. Therefore, concerted efforts are urgently needed to develop a new generation of vaccine that is risk-free and affordable and can be produced on a global scale. Here, we discuss the desired properties of a vaccine and methods to create a new polio vaccine.

Comment in

PMID:
18990066
[PubMed - indexed for MEDLINE]
PMCID:
PMC2596976
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk